Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib in Myelofibrosis Previously Treated with Ruxolitinib
NCT03755518Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of fedratinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Celgene Corporation. Started Mar 2019; status: terminated.
02
Drugs
fedratinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT03755518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755518.